Obesity and diabetes pharmaceutical treatments are on the brink of a major transformation. These drugs, including the recent FDA-approved Zepbound and others like Mounjaro, Wegovy and one that quickly became a household name, Ozempic, mimic natural gut hormones that regulate metabolism and suppress appetite.

Despite their efficacy—resulting in weight loss ranging from 10 to 25 per cent—these medications face major hurdles, including high production costs, complex storage needs and distribution challenges due to their injectable form.

In response, the pharmaceutical industry is exploring a significant shift toward oral solid dose forms—pills, tablets, capsules, etc. This move could address many current market barriers by simplifying production, reducing costs, enhancing patient accessibility, and improving compliance. Read more >